Oral Supplementation Compared With Hyaluronic Acid Infiltration in Rotator Cuff Tendinopathies
NCT ID: NCT06379997
Last Updated: 2024-08-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-08-10
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The present study aims to investigate the effectiveness of oral supplementation with a nutraceutical containing Collagen, Hyaluronic Acid, Vitamin C, and Manganese in functional outcome and pain reduction in cases of shoulder rotator cuff tendinopathy compared to a cycle of intra-articular hyaluronic acid injections.
The project involves the recruitment of 50 adult individuals presenting with shoulder pain and instrumental evidence of rotator cuff tendinopathy. All participants will receive one intra-articular injection of 1 ml of triamcinolone acetonide 40 mg. After the injection, participants will be divided into two groups according to Good Clinical Practice guidelines. One group will begin taking one vial per day for 56 days of an oral supplement containing Hyaluronic Acid, Collagen, Vitamin C, and Manganese (HA-COL) (Tendogenial®, B2Pharma) starting from the day following enrollment (Group 1). The other group will undergo a cycle of 3 intra-articular injections with hyaluronic acid (HA) (Hyalotend®, Fidia) (Group 2).
The hypothesis is that oral supplementation with HA-COL may have the same efficacy as intra-articular hyaluronic acid treatment in reducing pain and improving shoulder functionality.
Functional assessments will be conducted by a clinician unaware of the participants' group assignment. The following assessment scales will be used:
Numeric Rating Scale (NRS) for pain (from 0 to 10), evaluating 3 aspects of pain: 1) pain at rest, 2) nocturnal pain, 3) pain during movement.
Shoulder Disability Questionnaire (SDQ) for functionality.
Assessments will be conducted at the following time points:
T0) Before the administration of corticosteroid intra-articular injection (baseline).
T1) Seven days after the start of HA-COL intake for Group 1 and before the first intra-articular HA injection for Group 2 (T1, seven days from T0).
T2) At mid-cycle of oral HA-COL supplementation for Group 1 (28 days of intake) and seven days after the last HA injection for Group 2 (T2, 21 days from T1).
T3) Follow-up at 28 days from T2, at the end of the 56-day oral treatment cycle for Group 1, and 28 days after the last injection for Group 2 (T3, 56 days from T0).
The project involves the recruitment of 50 adult individuals presenting with shoulder pain and instrumental evidence of rotator cuff tendinopathy. All participants will receive one intra-articular injection of 1 ml of triamcinolone acetonide 40 mg. After the injection, participants will be divided into two groups according to Good Clinical Practice guidelines. One group will begin taking one vial per day for 56 days of an oral supplement containing Hyaluronic Acid, Collagen, Vitamin C, and Manganese (HA-COL) (Tendogenial®, B2Pharma) starting from the day following enrollment (Group 1). The other group will undergo a cycle of 3 intra-articular injections with hyaluronic acid (HA) (Hyalotend®, Fidia) (Group 2).
The hypothesis is that oral supplementation with HA-COL may have the same efficacy as intra-articular hyaluronic acid treatment in reducing pain and improving shoulder functionality.
Functional assessments will be conducted by a clinician unaware of the participants' group assignment. The following assessment scales will be used:
Numeric Rating Scale (NRS) for pain (from 0 to 10), evaluating 3 aspects of pain: 1) pain at rest, 2) nocturnal pain, 3) pain during movement.
Shoulder Disability Questionnaire (SDQ) for functionality.
Assessments will be conducted at the following time points:
T0) Before the administration of corticosteroid intra-articular injection (baseline).
T1) Seven days after the start of HA-COL intake for Group 1 and before the first intra-articular HA injection for Group 2 (T1, seven days from T0).
T2) At mid-cycle of oral HA-COL supplementation for Group 1 (28 days of intake) and seven days after the last HA injection for Group 2 (T2, 21 days from T1).
T3) Follow-up at 28 days from T2, at the end of the 56-day oral treatment cycle for Group 1, and 28 days after the last injection for Group 2 (T3, 56 days from T0).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
What Factors Are Associated With Prognosis of Rotator Cuff Disorder After Subacromial Hyaluronic Acid Injection
NCT03677895
Rotator Cuff Impingement Syndrome
UNKNOWN
NA
Comparison of Steroid, PRP,and PRP Plus Hyaluronic Acid Injection for Rotator Cuff Lesions.
NCT06237647
Rotator Cuff Lesions
RECRUITING
NA
Performance and Safety Evaluation of MD-Shoulder Collagen Medical Device in the Treatment of Rotator Cuff Syndrome
NCT05489484
Rotator Cuff Tendinitis
Syndrome Rotator Cuff
Tendinopathy
+2 more
COMPLETED
NA
Clinical Benefits and Safety of Tropho Tend in the Management of Painful Rotator Cuff Tendinopathy
NCT06809543
Rotator Cuff Tendinopathy
RECRUITING
NA
Corticosteroid Versus PRP Injections for Shoulder Tendinopathy
NCT07094178
Tendinopathy of Rotator Cuff
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background Shoulder pain is a prevalent symptom primarily affecting the adult population, with an incidence of approximately 19 per 1000 and a prevalence ranging from 7 to 26%, particularly affecting women. The primary cause of shoulder pain is rotator cuff pathology, characterized by nocturnal pain and weakness, especially during external rotation and elevation movements of the shoulder, attributable to excessive loading on the cuff tissues. These symptoms often result in disability and functional impairment.
The etiology of rotator cuff pathology appears multifactorial, often associated with chronic age-related degeneration characterized by a reduced ability to synthesize collagen, increased levels of free radicals, and heightened catabolic activity (5). Tendinopathies exhibit widespread structural changes, including increased apoptosis of tenocytes, collagen fiber disintegration leading to a decrease in collagen type I, an increase in collagen type III resulting in a reversal of the collagen I/III ratio, and ineffective neoangiogenesis.
As tendinopathy primarily represents a degenerative condition where the inflammatory component plays a minor role, current therapeutic strategies mainly focus on regenerative approaches. While intra-articular cortisone therapy has historically been utilized to alleviate pain from rotator cuff injuries, its potential detrimental effect on tendon collagen limits its long-term efficacy, rendering cortisone therapy beneficial only in the short term.
Conversely, intra-articular treatment with hyaluronic acid (HA) for rotator cuff injuries appears promising in reducing pain and improving shoulder function. A recent review analyzed 11 studies encompassing a total of 1102 patients. Low to medium molecular weight hyaluronic acids were utilized in these studies, with infiltration performed either via anatomical landmarks or ultrasound guidance, targeting either intra-articular or subacromial sites. Moreover, rare minor side effects (such as pain at the injection site or slight vagal effects) were reported, with no instances of allergic reactions.
Hyaluronic acid (HA) is a carbohydrate, specifically a mucopolysaccharide, naturally present in all living organisms. When unbound to other molecules, it binds to water, imparting a rigid viscous 'jelly-like' quality. HA serves as an integral component of synovial fluid, crucial for joint chondroprotection, and constitutes a significant portion of the tendon extracellular matrix.
Upon injection into a joint, HA diminishes cytokine-induced responses and reduces synovial inflammation, ultimately relieving pain and enhancing joint function. Notably, preclinical in vitro and in vivo studies have demonstrated that exogenous peritendinous HA possesses the ability to inhibit fibroblast activity and diminish the proinflammatory M1 activation state of macrophages.
Observations of improved lubrication, chondroprotection, and enhanced synovial fluid characteristics have also been reported. Additionally, HA facilitates tenocyte regeneration, modulates the ratio of collagen type I/III, and mitigates apoptosis and impaired angiogenesis.
It is important to note that in most studies, HA was not injected directly into the degenerated tendon but rather near and/or into the joint space. While it can be speculated that alterations in synovial fluid may positively impact the tendon itself, it remains plausible that clinical improvement could be secondary to the favorable effects on concomitant arthrosis frequently associated with the condition.
Rationale for Dietary Supplementation of Collagen and HA:
Tendons primarily comprise cells, predominantly tenoblasts along with endothelial cells and some chondrocytes, as well as proteoglycans, notably decorin and hyaluronic acid, and collagen, primarily type I. The tendon exhibits a highly organized extracellular matrix wherein collagen molecules assemble into filamentous collagen fibrils (formed by microfibrils), which further aggregate to constitute collagen fibers, the principal structural components.
Various reviews have assessed the effectiveness of oral collagen supplementation in enhancing tendon structure. Particularly, a review highlights that some studies have demonstrated promising clinical implications of collagen peptide supplementation in the prevention and treatment of tendinopathies, although conclusive evidence is still lacking. Another review indicates that collagen supplementation alongside physical training significantly influences pain relief, increased cross-sectional area, and tendon thickness . From a joint perspective, collagen supplementation enhances mobility and functionality while reducing pain.
Oral supplementation of hyaluronic acid has predominantly been investigated for its effects on joints. For instance, it has been found effective in ameliorating pain and enhancing the quality of life in patients with knee arthrosis, with sustained effects observed at 2 months . Furthermore, the combined administration of HA and collagen orally has shown to improve functional recovery in patients following anterior cruciate ligament reconstruction, with evidence from resonance imaging indicating improved neoligament maturation.
Experimental design In order to conduct this study, we will recruit 50 patients with rotator cuff injuries from the outpatient clinic of the Santa Lucia Foundation. A physiatrist from the clinic, participating in the project, will explain the study to the enrolled individuals and obtain their informed consent.
The enrolled patients will undergo infiltrative treatment with corticosteroids (Triamcinolone acetonide 40 mg, 1 vial - Kenacort®, BRISTOL-MYERS SQUIBB S.r.l.).
The enrolled patients will be randomized in 2 groups: oral supplements (Group 1 - G1) or intra-articular hyaluronic acid (Group 2 - G2).
The Experimental Group (G1) will begin taking a supplement called Tendogenial® (B2Pharma S.r.l.) the day after enrollment. This supplement contains Collagen, Hyaluronic Acid, Vitamin C, and Manganese. Each day for 28 days, participants in G1 will consume one vial of Tendogenial®.
Group 2 (G2) will receive three intra-articular injections of Hyalotend® (Fidia), a viscous solution of sodium salt hyaluronic acid (500-730 kDa) obtained by bacterial fermentation in buffered saline. The injections will be administered without ultrasound guidance, using pre-filled 20 mg/2 ml syringes. The route of administration will be intra-articular via the posterior access route.
Participants will be advised to take only paracetamol as needed for pain relief. Additionally, they will be instructed not to undergo physiotherapy during the study period. Any participants who undergo physiotherapy or receive other analgesic therapies during the study will be excluded from the statistical analysis.
Inclusion Criteria:
Persistent shoulder pain lasting for at least 2 months, unresponsive to conservative treatment (nonsteroidal anti-inflammatory drugs \[NSAIDs\] and rehabilitation).
Ultrasound or MRI evidence of a rotator cuff lesion without complete tendon rupture.
Limited active range of motion (ROM) in the shoulder. Age between 30 and 80 years. Willingness to provide informed consent to participate in the study.
Exclusion Criteria:
Traumatic shoulder injury as the cause of pain. History of shoulder dislocation, fracture, or previous shoulder surgery. Presence of signs indicating ligamentous instability. Severe shoulder arthrosis, adhesive capsulitis, or calcific tendinitis. Previous infiltrative treatment with corticosteroids, hyaluronic acid, or collagen within the past 6 months.
Diagnosis of rheumatic or neoplastic diseases. Ongoing therapy with anticoagulants. Cervical radiculopathy. Pregnancy. History of heart, kidney, or liver failure. Cognitive impairment.
Both study groups will undergo assessment using pain and functional scales by a clinician who is blinded to the treatment group.
In addition to providing informed consent to participate in the study, participants will also sign a consent form specifically for infiltration, prepared by the Santa Lucia Foundation. Any adverse reactions or side effects experienced by participants will be documented and reported.
The etiology of rotator cuff pathology appears multifactorial, often associated with chronic age-related degeneration characterized by a reduced ability to synthesize collagen, increased levels of free radicals, and heightened catabolic activity (5). Tendinopathies exhibit widespread structural changes, including increased apoptosis of tenocytes, collagen fiber disintegration leading to a decrease in collagen type I, an increase in collagen type III resulting in a reversal of the collagen I/III ratio, and ineffective neoangiogenesis.
As tendinopathy primarily represents a degenerative condition where the inflammatory component plays a minor role, current therapeutic strategies mainly focus on regenerative approaches. While intra-articular cortisone therapy has historically been utilized to alleviate pain from rotator cuff injuries, its potential detrimental effect on tendon collagen limits its long-term efficacy, rendering cortisone therapy beneficial only in the short term.
Conversely, intra-articular treatment with hyaluronic acid (HA) for rotator cuff injuries appears promising in reducing pain and improving shoulder function. A recent review analyzed 11 studies encompassing a total of 1102 patients. Low to medium molecular weight hyaluronic acids were utilized in these studies, with infiltration performed either via anatomical landmarks or ultrasound guidance, targeting either intra-articular or subacromial sites. Moreover, rare minor side effects (such as pain at the injection site or slight vagal effects) were reported, with no instances of allergic reactions.
Hyaluronic acid (HA) is a carbohydrate, specifically a mucopolysaccharide, naturally present in all living organisms. When unbound to other molecules, it binds to water, imparting a rigid viscous 'jelly-like' quality. HA serves as an integral component of synovial fluid, crucial for joint chondroprotection, and constitutes a significant portion of the tendon extracellular matrix.
Upon injection into a joint, HA diminishes cytokine-induced responses and reduces synovial inflammation, ultimately relieving pain and enhancing joint function. Notably, preclinical in vitro and in vivo studies have demonstrated that exogenous peritendinous HA possesses the ability to inhibit fibroblast activity and diminish the proinflammatory M1 activation state of macrophages.
Observations of improved lubrication, chondroprotection, and enhanced synovial fluid characteristics have also been reported. Additionally, HA facilitates tenocyte regeneration, modulates the ratio of collagen type I/III, and mitigates apoptosis and impaired angiogenesis.
It is important to note that in most studies, HA was not injected directly into the degenerated tendon but rather near and/or into the joint space. While it can be speculated that alterations in synovial fluid may positively impact the tendon itself, it remains plausible that clinical improvement could be secondary to the favorable effects on concomitant arthrosis frequently associated with the condition.
Rationale for Dietary Supplementation of Collagen and HA:
Tendons primarily comprise cells, predominantly tenoblasts along with endothelial cells and some chondrocytes, as well as proteoglycans, notably decorin and hyaluronic acid, and collagen, primarily type I. The tendon exhibits a highly organized extracellular matrix wherein collagen molecules assemble into filamentous collagen fibrils (formed by microfibrils), which further aggregate to constitute collagen fibers, the principal structural components.
Various reviews have assessed the effectiveness of oral collagen supplementation in enhancing tendon structure. Particularly, a review highlights that some studies have demonstrated promising clinical implications of collagen peptide supplementation in the prevention and treatment of tendinopathies, although conclusive evidence is still lacking. Another review indicates that collagen supplementation alongside physical training significantly influences pain relief, increased cross-sectional area, and tendon thickness . From a joint perspective, collagen supplementation enhances mobility and functionality while reducing pain.
Oral supplementation of hyaluronic acid has predominantly been investigated for its effects on joints. For instance, it has been found effective in ameliorating pain and enhancing the quality of life in patients with knee arthrosis, with sustained effects observed at 2 months . Furthermore, the combined administration of HA and collagen orally has shown to improve functional recovery in patients following anterior cruciate ligament reconstruction, with evidence from resonance imaging indicating improved neoligament maturation.
Experimental design In order to conduct this study, we will recruit 50 patients with rotator cuff injuries from the outpatient clinic of the Santa Lucia Foundation. A physiatrist from the clinic, participating in the project, will explain the study to the enrolled individuals and obtain their informed consent.
The enrolled patients will undergo infiltrative treatment with corticosteroids (Triamcinolone acetonide 40 mg, 1 vial - Kenacort®, BRISTOL-MYERS SQUIBB S.r.l.).
The enrolled patients will be randomized in 2 groups: oral supplements (Group 1 - G1) or intra-articular hyaluronic acid (Group 2 - G2).
The Experimental Group (G1) will begin taking a supplement called Tendogenial® (B2Pharma S.r.l.) the day after enrollment. This supplement contains Collagen, Hyaluronic Acid, Vitamin C, and Manganese. Each day for 28 days, participants in G1 will consume one vial of Tendogenial®.
Group 2 (G2) will receive three intra-articular injections of Hyalotend® (Fidia), a viscous solution of sodium salt hyaluronic acid (500-730 kDa) obtained by bacterial fermentation in buffered saline. The injections will be administered without ultrasound guidance, using pre-filled 20 mg/2 ml syringes. The route of administration will be intra-articular via the posterior access route.
Participants will be advised to take only paracetamol as needed for pain relief. Additionally, they will be instructed not to undergo physiotherapy during the study period. Any participants who undergo physiotherapy or receive other analgesic therapies during the study will be excluded from the statistical analysis.
Inclusion Criteria:
Persistent shoulder pain lasting for at least 2 months, unresponsive to conservative treatment (nonsteroidal anti-inflammatory drugs \[NSAIDs\] and rehabilitation).
Ultrasound or MRI evidence of a rotator cuff lesion without complete tendon rupture.
Limited active range of motion (ROM) in the shoulder. Age between 30 and 80 years. Willingness to provide informed consent to participate in the study.
Exclusion Criteria:
Traumatic shoulder injury as the cause of pain. History of shoulder dislocation, fracture, or previous shoulder surgery. Presence of signs indicating ligamentous instability. Severe shoulder arthrosis, adhesive capsulitis, or calcific tendinitis. Previous infiltrative treatment with corticosteroids, hyaluronic acid, or collagen within the past 6 months.
Diagnosis of rheumatic or neoplastic diseases. Ongoing therapy with anticoagulants. Cervical radiculopathy. Pregnancy. History of heart, kidney, or liver failure. Cognitive impairment.
Both study groups will undergo assessment using pain and functional scales by a clinician who is blinded to the treatment group.
In addition to providing informed consent to participate in the study, participants will also sign a consent form specifically for infiltration, prepared by the Santa Lucia Foundation. Any adverse reactions or side effects experienced by participants will be documented and reported.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Tendinitis of Shoulder
Hyaluronic Acid
Dietary Supplements
Shoulder Pain
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
The enrolled patients will be randomized in two groups: treated with oral supplements (Group 1 - G1) or with intra-articular hyaluronic acid (Group 2 - G2)
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Investigators
Both study groups will undergo assessment using pain and functional scales by a clinician who is blinded to the treatment group
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral supplemention
Assumption of 1 vial/day starting from the day after enrollment for 56 days. This supplement contains Collagen, Hyaluronic Acid, Vitamin C, and Manganese.
Group Type
ACTIVE_COMPARATOR
Collagen, Hyaluronic Acid, Vitamin C, and Manganese
Intervention Type
DIETARY_SUPPLEMENT
The Group 1 (G1) will begin taking a dietary supplement the day after enrollment.
Intra-articolar infiltration
Intra-articular injections of a viscous solution of sodium salt hyaluronic acid (500-730 kDa) in pre-filled 20 mg/2 ml syringes, 1/week for 3 weeks.
Group Type
ACTIVE_COMPARATOR
Intra-articular infiltration
Intervention Type
DRUG
Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collagen, Hyaluronic Acid, Vitamin C, and Manganese
The Group 1 (G1) will begin taking a dietary supplement the day after enrollment.
Intervention Type
DIETARY_SUPPLEMENT
Intra-articular infiltration
Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Tendogenial
Hyalotend
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persistent shoulder pain lasting for at least 2 months unresponsive to conservative treatment (nonsteroidal anti-inflammatory drugs \[NSAIDs\] and rehabilitation)
* Ultrasound or MRI evidence of a rotator cuff lesion without complete tendon rupture
* Limited active range of motion (ROM) in the shoulder
* Ultrasound or MRI evidence of a rotator cuff lesion without complete tendon rupture
* Limited active range of motion (ROM) in the shoulder
Exclusion Criteria
* Traumatic shoulder injury as the cause of pain
* History of shoulder dislocation, fracture, or previous shoulder surgery
* Presence of signs indicating ligamentous instability
* Severe shoulder arthrosis, adhesive capsulitis, or calcific tendinitis
* Previous infiltrative treatment with corticosteroids, hyaluronic acid, or collagen within the past 6 months
* Diagnosis of rheumatic or neoplastic diseases
* Ongoing therapy with anticoagulants
* Cervical radiculopathy
* Pregnancy
* History of heart, kidney, or liver failure
* Cognitive impairment
* History of shoulder dislocation, fracture, or previous shoulder surgery
* Presence of signs indicating ligamentous instability
* Severe shoulder arthrosis, adhesive capsulitis, or calcific tendinitis
* Previous infiltrative treatment with corticosteroids, hyaluronic acid, or collagen within the past 6 months
* Diagnosis of rheumatic or neoplastic diseases
* Ongoing therapy with anticoagulants
* Cervical radiculopathy
* Pregnancy
* History of heart, kidney, or liver failure
* Cognitive impairment
Minimum Eligible Age
30 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
I.R.C.C.S. Fondazione Santa Lucia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefano Brunelli
Principal Investigator, MD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefano Brunelli, MD
Role: STUDY_DIRECTOR
I.R.C.C.S. Fondazione Santa Lucia, Roma, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
I.R.C.C.S. Fondazione Santa Lucia
Roma, RM, Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Luime JJ, Koes BW, Hendriksen IJ, Burdorf A, Verhagen AP, Miedema HS, Verhaar JA. Prevalence and incidence of shoulder pain in the general population; a systematic review. Scand J Rheumatol. 2004;33(2):73-81. doi: 10.1080/03009740310004667.
Reference Type
BACKGROUND
Greving K, Dorrestijn O, Winters JC, Groenhof F, van der Meer K, Stevens M, Diercks RL. Incidence, prevalence, and consultation rates of shoulder complaints in general practice. Scand J Rheumatol. 2012 Mar;41(2):150-5. doi: 10.3109/03009742.2011.605390. Epub 2011 Sep 21.
Reference Type
BACKGROUND
Dabija DI, Gao C, Edwards TL, Kuhn JE, Jain NB. Genetic and familial predisposition to rotator cuff disease: a systematic review. J Shoulder Elbow Surg. 2017 Jun;26(6):1103-1112. doi: 10.1016/j.jse.2016.11.038. Epub 2017 Feb 2.
Reference Type
BACKGROUND
Herrmann SJ, Izadpanah K, Sudkamp NP, Strohm PC. Tears of the rotator cuff. Causes--diagnosis--treatment. Acta Chir Orthop Traumatol Cech. 2014;81(4):256-66.
Reference Type
BACKGROUND
Via AG, De Cupis M, Spoliti M, Oliva F. Clinical and biological aspects of rotator cuff tears. Muscles Ligaments Tendons J. 2013 Jul 9;3(2):70-9. doi: 10.11138/mltj/2013.3.2.070. Print 2013 Apr.
Reference Type
BACKGROUND
Ackermann PW, Renstrom P. Tendinopathy in sport. Sports Health. 2012 May;4(3):193-201. doi: 10.1177/1941738112440957.
Reference Type
BACKGROUND
Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751-67. doi: 10.1016/S0140-6736(10)61160-9. Epub 2010 Oct 21.
Reference Type
BACKGROUND
van der Worp H, van den Akker-Scheek I, van Schie H, Zwerver J. ESWT for tendinopathy: technology and clinical implications. Knee Surg Sports Traumatol Arthrosc. 2013 Jun;21(6):1451-8. doi: 10.1007/s00167-012-2009-3. Epub 2012 May 1.
Reference Type
BACKGROUND
Osti L, Buda M, Buono AD, Osti R, Massari L. Clinical evidence in the treatment of rotator cuff tears with hyaluronic acid. Muscles Ligaments Tendons J. 2016 Feb 13;5(4):270-5. doi: 10.11138/mltj/2015.5.4.270. eCollection 2015 Oct-Dec.
Reference Type
BACKGROUND
Lee LC, Lieu FK, Lee HL, Tung TH. Effectiveness of hyaluronic acid administration in treating adhesive capsulitis of the shoulder: a systematic review of randomized controlled trials. Biomed Res Int. 2015;2015:314120. doi: 10.1155/2015/314120. Epub 2015 Jan 31.
Reference Type
BACKGROUND
Salamanna F, Frizziero A, Pagani S, Giavaresi G, Curzi D, Falcieri E, Marini M, Abruzzo PM, Martini L, Fini M. Metabolic and cytoprotective effects of in vivo peri-patellar hyaluronic acid injections in cultured tenocytes. Connect Tissue Res. 2015 Feb;56(1):35-43. doi: 10.3109/03008207.2014.979166. Epub 2014 Nov 13.
Reference Type
BACKGROUND
Iwata H. Pharmacologic and clinical aspects of intraarticular injection of hyaluronate. Clin Orthop Relat Res. 1993 Apr;(289):285-91.
Reference Type
BACKGROUND
Oliva F, Marsilio E, Asparago G, Frizziero A, Berardi AC, Maffulli N. The Impact of Hyaluronic Acid on Tendon Physiology and Its Clinical Application in Tendinopathies. Cells. 2021 Nov 9;10(11):3081. doi: 10.3390/cells10113081.
Reference Type
BACKGROUND
Abate M, Schiavone C, Salini V. The use of hyaluronic acid after tendon surgery and in tendinopathies. Biomed Res Int. 2014;2014:783632. doi: 10.1155/2014/783632. Epub 2014 May 8.
Reference Type
BACKGROUND
Franchi M, Trire A, Quaranta M, Orsini E, Ottani V. Collagen structure of tendon relates to function. ScientificWorldJournal. 2007 Mar 30;7:404-20. doi: 10.1100/tsw.2007.92.
Reference Type
BACKGROUND
Hijlkema A, Roozenboom C, Mensink M, Zwerver J. The impact of nutrition on tendon health and tendinopathy: a systematic review. J Int Soc Sports Nutr. 2022 Aug 3;19(1):474-504. doi: 10.1080/15502783.2022.2104130. eCollection 2022.
Reference Type
BACKGROUND
Boldt KS, Olson BL, Thiele RM. Effects of Collagen and Exercise on Tendon Properties and Pain: A Critically Appraised Topic. J Sport Rehabil. 2023 Sep 27;32(8):938-941. doi: 10.1123/jsr.2023-0115. Print 2023 Nov 1.
Reference Type
BACKGROUND
Campos LD, Santos Junior VA, Pimentel JD, Carrega GLF, Cazarin CBB. Collagen supplementation in skin and orthopedic diseases: A review of the literature. Heliyon. 2023 Mar 28;9(4):e14961. doi: 10.1016/j.heliyon.2023.e14961. eCollection 2023 Apr.
Reference Type
BACKGROUND
Kalman DS, Heimer M, Valdeon A, Schwartz H, Sheldon E. Effect of a natural extract of chicken combs with a high content of hyaluronic acid (Hyal-Joint) on pain relief and quality of life in subjects with knee osteoarthritis: a pilot randomized double-blind placebo-controlled trial. Nutr J. 2008 Jan 21;7:3. doi: 10.1186/1475-2891-7-3.
Reference Type
BACKGROUND
Lopez-Vidriero E, Olive-Vilas R, Lopez-Capape D, Varela-Sende L, Lopez-Vidriero R, Til-Perez L. Efficacy and Tolerability of Progen, a Nutritional Supplement Based on Innovative Plasma Proteins, in ACL Reconstruction: A Multicenter Randomized Controlled Trial. Orthop J Sports Med. 2019 Feb 27;7(2):2325967119827237. doi: 10.1177/2325967119827237. eCollection 2019 Feb.
Reference Type
BACKGROUND
Leon-Lopez A, Morales-Penaloza A, Martinez-Juarez VM, Vargas-Torres A, Zeugolis DI, Aguirre-Alvarez G. Hydrolyzed Collagen-Sources and Applications. Molecules. 2019 Nov 7;24(22):4031. doi: 10.3390/molecules24224031.
Reference Type
BACKGROUND
Clark KL, Sebastianelli W, Flechsenhar KR, Aukermann DF, Meza F, Millard RL, Deitch JR, Sherbondy PS, Albert A. 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain. Curr Med Res Opin. 2008 May;24(5):1485-96. doi: 10.1185/030079908x291967. Epub 2008 Apr 15.
Reference Type
BACKGROUND
Noriega-Gonzalez DC, Drobnic F, Caballero-Garcia A, Roche E, Perez-Valdecantos D, Cordova A. Effect of Vitamin C on Tendinopathy Recovery: A Scoping Review. Nutrients. 2022 Jun 27;14(13):2663. doi: 10.3390/nu14132663.
Reference Type
BACKGROUND
Ozgen M, Firat S, Sarsan A, Topuz O, Ardic F, Baydemir C. Short- and long-term results of clinical effectiveness of sodium hyaluronate injection in supraspinatus tendinitis. Rheumatol Int. 2012 Jan;32(1):137-44. doi: 10.1007/s00296-010-1577-0. Epub 2010 Jul 31.
Reference Type
BACKGROUND
Croft P, Pope D, Zonca M, O'Neill T, Silman A. Measurement of shoulder related disability: results of a validation study. Ann Rheum Dis. 1994 Aug;53(8):525-8. doi: 10.1136/ard.53.8.525.
Reference Type
BACKGROUND
Brindisino F, Pellicciari L, Lorusso M, Pennella D, Padua R, Di Bari M. Cross-cultural adaptation, reliability, and validity of the Italian version of the Shoulder Disability Questionnaire. Musculoskelet Sci Pract. 2020 Apr;46:102123. doi: 10.1016/j.msksp.2020.102123. Epub 2020 Jan 31.
Reference Type
BACKGROUND
Chou WY, Ko JY, Wang FS, Huang CC, Wong T, Wang CJ, Chang HE. Effect of sodium hyaluronate treatment on rotator cuff lesions without complete tears: a randomized, double-blind, placebo-controlled study. J Shoulder Elbow Surg. 2010 Jun;19(4):557-63. doi: 10.1016/j.jse.2009.08.006. Epub 2009 Dec 5.
Reference Type
BACKGROUND
Moghtaderi A, Sajadiyeh S, Khosrawi S, Dehghan F, Bateni V. Effect of subacromial sodium hyaluronate injection on rotator cuff disease: A double-blind placebo-controlled clinical trial. Adv Biomed Res. 2013 Nov 30;2:89. doi: 10.4103/2277-9175.122517. eCollection 2013.
Reference Type
BACKGROUND
Byun SD, Park DH, Choi WD, Lee ZI. Subacromial Bursa Injection of Hyaluronate with Steroid in Patients with Peri-articular Shoulder Disorders. Ann Rehabil Med. 2011 Oct;35(5):664-72. doi: 10.5535/arm.2011.35.5.664. Epub 2011 Oct 31.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SANTA LUCIA IRCCS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Rotator Cuff Tendinopathy Conservative Treatment With Collagen, PRP or Both
NCT04492748
UNKNOWN
PHASE4
Connective Tissue Matrix for Rotator Cuff Tendinopathy
NCT06160427
ACTIVE_NOT_RECRUITING
PHASE4
Exercise vs. Supplements in Rotator Cuff-Related Shoulder Pain
NCT05976035
NOT_YET_RECRUITING
NA
Single Shot vs Continuous Interscalene Block for Rotator Cuff Repair
NCT01122745
COMPLETED
Hyaluronic Acid in Shoulder Tendinopathy
NCT06376981
RECRUITING
PHASE3
Comparison of Strength and Constant Score Pre- and Post-Subacromial Injection for Full Thickness Rotator Cuff Tears
NCT02693444
WITHDRAWN
NA
Nutritional Supplementation Effects on Rehabilitation Outcomes in Rotator Cuff Pathology
NCT01798693
TERMINATED
EARLY_PHASE1
Study of 25% Dextrose Injections in Shoulder Ligaments and Tendons to Promote Their Healing
NCT01402011
COMPLETED
NA
Combination of Vitamin C and N-Acetylcysteine to Improve Functional Outcome After Rotator Cuff Repair
NCT06384833
NOT_YET_RECRUITING
PHASE4
Effect of Extracorporeal Shock Wave Combined With Autologous Platelet-rich Plasma Injection on Rotator Cuff Calcific Tendinitis
NCT06372600
NOT_YET_RECRUITING
NA
The Efficacy of PRP Injection in the Treatment of Rotator Cuff Syndrome
NCT05561452
COMPLETED
NA
Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy
NCT06712290
WITHDRAWN
NA
Platelet Rich Plasm Versus Hyaluronic Acid Injection in Chronic Painful Shoulder
NCT05072899
COMPLETED
NA
Comparison of Hyaluronic Acid, PRP and Steroid Injections in Partial Rotator Cuff Tears: A Prospective Randomized Study
NCT04681937
UNKNOWN
NA
Atelocollagen ＆ Hyaluronic Acid Correlation With Enhancement of Rotator Cuff Healing: Synergistic Effect?
NCT07285746
ACTIVE_NOT_RECRUITING
NA
Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy
NCT02971072
COMPLETED
NA
Platelet-rich Plasma in Calcific Tendinitis
NCT02173743
COMPLETED
NA
Ultrasound Guided Steroids Injection Versus PRP for Shoulder Pain Relief
NCT05317624
COMPLETED
EARLY_PHASE1
Prolotherapy Intervention in Patient With Frozen Shoulder
NCT05131269
COMPLETED
PHASE4
Subacromial Corticosteroid Injections and tDCS in Rotator Cuff Tendinopathy
NCT03967574
COMPLETED
NA
Subacromial Injection of Allogeneic Platelet Rich Plasma (PRP) for Shoulder Impingement Syndrome
NCT02019537
COMPLETED
NA
Platelet-rich Plasma Injections and Physiotherapy in the Treatment of Chronic Rotator Cuff Tendinopathy
NCT03133416
COMPLETED
NA
Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair
NCT02992028
UNKNOWN
PHASE4
Effect of PRP vs Corticosteroid in Rotator Cuff Tendinopathy Subtypes in Arthroscopic Repair
NCT05603468
RECRUITING
PHASE4